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Reply to the Editor:
Dr Van Schil’s letter clearly enunciates the
concern of many surgeons that the combina-
tion of chemotherapy and radiation for in-
duction increases the risk of subsequent
surgical intervention, whereas the use of
induction chemotherapy alone does not.
Although the report from Martin and
colleagues,1 as well as the data from the In-
tergroup 0139 trial,2 support this concern,
we believe this not to be the case. In our ex-
perience, as outlined in our report, the mor-
talities all occurred early in our experience
with this protocol. There were no mortalities
in the last 34 patients, including those
undergoing pneumonectomy. In doing the
chart audit, we noted that the mortalities in
the patients undergoing pneumonectomy
occurred in patients with large, bulky central
tumors, in whom the hilar dissection could
be anticipated to be difficult. In retrospect,
we would now not consider such patients
for resection. Based on our own experience,
we do not think that induction chemoradia-
tion results in excessive risk for resection
if patients are selected appropriately. Fur-
thermore, this is supported by the work of
Sonett and colleagues,3 who used even
higher doses of radiation without any oper-
ative mortality.
In selecting patients for trimodality ther-
apy, we believe that both the primary and
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To the Editor:
I read with great interest the recent article
of the Toronto group on improved results
of induction chemoradiation followed by sur-
gery for selected patients with stage IIIA-N2
non–small cell lung cancer.1 Uy and col-
leagues1 are to be congratulated for their
detailed analysis and honest data reporting
regarding this difficult subset of patients
with N2 disease for whom the optimal treat-
ment remains to be defined. As in the Inter-
group-0139 trial,2 Uy and colleagues1
adopted an induction therapy of concurrent
chemotherapy and radiotherapy, followed
by surgical resection if there was no progres-
sive disease on restaging. In 11 cases
(27.5%), pneumonectomy was necessary.
As previously observed in the INT-0139 trial,
mortality in this setting was high: 27% over-
all, and even 50% for complex pneumonecto-
mies. Causes of death were adult respiratory
distress syndrome and postoperative hemor-
rhage. After induction therapy followed by718 The Journal of Thoracic and Cardiopneumonectomy, higher incidences have
been reported for empyema, bronchopleural
fistula, and adult respiratory distress syn-
drome than are seen after standard resection
without induction therapy.3
Uy and colleagues1 referred to European
Organization for Research and Treatment of
Cancer trial 08941, results of which were
recently reported.3,4 In this multicenter trial,
patients with histologically proven stage
IIIA-N2 non–small cell lung cancer were
treated with induction chemotherapy—
without radiotherapy—and in case of
response were subsequently randomly as-
signed to undergo either surgery or radio-
therapy. Pneumonectomy was performed in
46.8% of patients; the 30-day mortality in
this subgroup was 6.9%, which was much
lower than those reported by Uy and col-
leagues1 and in the INT-0139 trial.2 Similar
results as in the EORTC 08941 study were
recently published by a group from Stras-
bourg; they reported a 30-day mortality of
6.7% in a series of 60 patients under-
going pneumonectomy after induction
chemotherapy.5
Although Uy and colleagues1 did not
specifically comment on this issue, the
type of induction therapy—chemotherapy
versus combined chemoradiotherapy—
may be important in explaining this mortal-
ity difference. Unfortunately, there are no
randomized studies directly comparing in-
duction chemotherapy with chemoradio-
therapy with respect to outcome after
surgical resection for locally advanced
non–small cell lung cancer.
Although a pneumonectomy can be
safely performed after induction chemother-
apy, it remains a high-risk procedure after
induction chemoradiotherapy, especially
when a complex procedure has to be per-
formed on the right side. Coverage of the
bronchial stump with viable tissue is essen-
tial to prevent the dreadful complication of
bronchial stump dehiscence.
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